Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NYSE:ATNM NASDAQ:ESLA NASDAQ:MRKR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$2.22+3.3%$1.82$1.21▼$3.81$54.83M0.68261,100 shs118,451 shsATNMActinium Pharmaceuticals$1.58-0.3%$1.64$1.03▼$2.41$49.13M-0.25365,836 shs53,124 shsESLAEstrella Immunopharma$1.30+3.3%$1.03$0.63▼$1.78$48.56M0.39103,909 shs193,410 shsMRKRMarker Therapeutics$1.06$1.05$0.81▼$5.95$13.72M1.47755,197 shs226,745 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+9.69%+11.98%+18.13%+8.04%+10.82%ATNMActinium Pharmaceuticals+1.28%-1.25%0.00%0.00%-4.82%ESLAEstrella Immunopharma-10.02%+5.06%+19.97%+40.59%+13.49%MRKRMarker Therapeutics-1.85%+18.75%+18.20%-41.44%-61.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$2.22+3.3%$1.82$1.21▼$3.81$54.83M0.68261,100 shs118,451 shsATNMActinium Pharmaceuticals$1.58-0.3%$1.64$1.03▼$2.41$49.13M-0.25365,836 shs53,124 shsESLAEstrella Immunopharma$1.30+3.3%$1.03$0.63▼$1.78$48.56M0.39103,909 shs193,410 shsMRKRMarker Therapeutics$1.06$1.05$0.81▼$5.95$13.72M1.47755,197 shs226,745 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+9.69%+11.98%+18.13%+8.04%+10.82%ATNMActinium Pharmaceuticals+1.28%-1.25%0.00%0.00%-4.82%ESLAEstrella Immunopharma-10.02%+5.06%+19.97%+40.59%+13.49%MRKRMarker Therapeutics-1.85%+18.75%+18.20%-41.44%-61.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/AATNMActinium Pharmaceuticals 3.00Buy$4.50185.71% UpsideESLAEstrella Immunopharma 2.00Hold$16.001,129.82% UpsideMRKRMarker Therapeutics 3.00Buy$13.171,142.14% UpsideCurrent Analyst Ratings BreakdownLatest MRKR, ATNM, ESLA, and AADI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ESLAEstrella ImmunopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MRKRMarker TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ESLAEstrella ImmunopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MRKRMarker TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/12/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M2.19N/AN/A$4.29 per share0.52ATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AN/AMRKRMarker Therapeutics$6.59M2.08N/AN/A$1.73 per share0.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%11/4/2025 (Estimated)ATNMActinium Pharmaceuticals-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/AESLAEstrella ImmunopharmaN/A-$0.26N/A∞N/AN/A-1,132.38%-358.54%11/13/2025 (Estimated)MRKRMarker Therapeutics-$10.73M-$1.37N/AN/AN/A-271.12%-114.59%-90.31%11/13/2025 (Estimated)Latest MRKR, ATNM, ESLA, and AADI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MRKRMarker Therapeutics-$0.55-$0.29+$0.26-$0.29$0.72 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54ATNMActinium PharmaceuticalsN/A10.2510.25ESLAEstrella ImmunopharmaN/A0.160.16MRKRMarker TherapeuticsN/A3.453.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%ATNMActinium Pharmaceuticals27.50%ESLAEstrella Immunopharma0.35%MRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%ATNMActinium Pharmaceuticals6.00%ESLAEstrella Immunopharma55.10%MRKRMarker Therapeutics7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableESLAEstrella ImmunopharmaN/A37.07 million16.64 millionNot OptionableMRKRMarker Therapeutics6012.94 million11.93 millionNot OptionableMRKR, ATNM, ESLA, and AADI HeadlinesRecent News About These CompaniesMarker Therapeutics Launches Phase 1 RAPID Trial for Multi-Antigen Recognizing T Cells as Off-the-Shelf Treatment for AML and MDSOctober 6 at 7:50 AM | quiverquant.comQMarker Therapeutics Announces First Patient Treated in Off-the-Shelf ProgramOctober 6 at 7:30 AM | globenewswire.comMarker Therapeutics, Inc. (NASDAQ:MRKR) Receives $13.17 Consensus Target Price from AnalystsOctober 6 at 4:01 AM | americanbankingnews.comMarker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28, 2025 | globenewswire.comMarker Therapeutics (MRKR) Falls 20.6% After Positive Clinical StudyAugust 27, 2025 | insidermonkey.comMarker Therapeutics stock soars on promising Phase 1 lymphoma study dataAugust 26, 2025 | investing.comMarker Therapeutics provides update on observations from Phase 1 APOLLO studyAugust 26, 2025 | msn.comMarker Therapeutics Stock Drops After Report About Lymphoma TreatmentAugust 26, 2025 | benzinga.comMarker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed LymphomaAugust 26, 2025 | globenewswire.comMarker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | globenewswire.comMarker Therapeutics Insider Trading Activity | NASDAQ:MRKR | BenzingaJuly 18, 2025 | benzinga.comHere's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn SituationJuly 11, 2025 | finance.yahoo.comMarker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with LymphomaJune 17, 2025 | globenewswire.comMarker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with LymphomaMay 20, 2025 | globenewswire.comMarker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell TherapiesMay 19, 2025 | globenewswire.comArkansas Historic Preservation Program hosts National Historic Marker WeekendApril 17, 2025 | stuttgartdailyleader.comSMarker Therapeutics (MRKR) Receives a Buy from Canaccord GenuityApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology ConferenceApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology ConferenceApril 1, 2025 | globenewswire.comMarker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last yearMarch 31, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get?By Sam Quirke | September 12, 2025Tesla: 3 Reasons October’s Earnings Will Make or Break the StockBy Sam Quirke | September 23, 2025Rivian Is Emerging as a Supplemental Tesla PlayBy Jordan Chussler | September 26, 2025The BYD Opportunity: Tesla-Like Growth at a Fraction of the PriceBy Leo Miller | September 26, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025MRKR, ATNM, ESLA, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$2.22 +0.07 (+3.26%) As of 10/7/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Actinium Pharmaceuticals NYSE:ATNM$1.58 -0.01 (-0.32%) As of 01:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Estrella Immunopharma NASDAQ:ESLA$1.30 +0.04 (+3.28%) As of 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Marker Therapeutics NASDAQ:MRKR$1.06 0.00 (0.00%) As of 01:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Will Firefly’s $855M SciTec Acquisition Ignite a Stock Re-Rating? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
